News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
New and experimental HIV treatments
HIV attachment inhibitor BMS-663068 matches atazanavir in phase 2b study

Bristol-Myers Squibb’s HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study

Published
14 October 2015
By
Liz Highleyman
Prevention of mother-to-child transmission
Raltegravir appears to prevent mother-to-child HIV transmission during late pregnancy

Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment for pregnant women with HIV –

Published
28 July 2015
By
Liz Highleyman
Resistance
Exploring possible treatment options after virological failure with raltegravir

In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

Published
21 January 2015
From
CATIE
The search for a cure
British HIV cure survey: most respondents would be prepared to take some health risk to help find a cure for HIV

An online survey that asked people living with HIV, largely from the UK, whether they would participate in HIV cure research, has found that the majority of

Published
28 November 2014
By
Gus Cairns
Treatment outcomes and life expectancy
Higher pill burden is associated with poorer adherence to HIV therapy and reduced chances of achieving an undetectable viral load

Lower pill burden is associated with higher rates of adherence to HIV treatment and better virological outcomes, according to the results of a meta-analysis published in the online

Published
31 January 2014
By
Michael Carter
Resistance
Janssen to Stop Offering "Virtual Phenotype" Testing, and Musings on Progress

As is plainly obvious to anyone doing HIV care, the incidence of new patients with the sort of HIV drug resistance for which the test was developed has plummeted. There simply aren't many new patients out there who have multiple mutations, especially in the PI-drug class, and who will need the computational black-box firepower provided by a vircoTYPE.

Published
27 November 2013
From
The BodyPRO
Finance and funding
Second- and Third-Line ART Cost 24% and 41% More Than First Line in US

Second-line antiretroviral therapy (ART) costs 24% more per year than first-line therapy in the United States, and third-line therapy costs 41% more than first-line therapy, according to a large insurance claims-based analysis.

Published
17 September 2013
From
NATAP
Treatment-experienced people
No Dose Adjustment With Etravirine Plus ATV/r in Treatment Experienced: Randomized Trial

After 48 weeks of the randomized TEACH trial, virologic responses were equivalent when antiretroviral-experienced people took standard-dose etravirine with 300/100 or 400/100 mg of atazanavir/ritonavir daily.

Published
22 July 2013
From
NATAP
Access to medicines and treatment
Third-line ARVs could widen treatment gap in Zimbabwe

HIV/AIDS activists in Zimbabwe have welcomed the government's move to address the problem of HIV drug resistance by introducing third-line antiretroviral drug (ARVs). But it remains unclear how the cash-strapped government will finance this, as procuring the drugs will invariably be expensive and could divert resources away from other HIV treatment efforts.

Published
12 March 2013
From
IRIN Plus News
Treatment-experienced people
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster

Published
10 March 2013
By
Liz Highleyman
← Prev12345...16Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.